<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219865</url>
  </required_header>
  <id_info>
    <org_study_id>NJYK-CPEDRV-I</org_study_id>
    <nct_id>NCT04219865</nct_id>
  </id_info>
  <brief_title>Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection</brief_title>
  <official_title>Study on the Safety, Tolerance and Pharmacokinetics of Single-dose, Increasing and Loading Dose and Maintenance Dose Sequential Intravenous Infusion of Compound Edaravone Injection in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on the Safety, Tolerance and Pharmacokinetics of Single-dose, Increasing and Loading
      Dose and Maintenance Dose Sequential Intravenous Infusion of Compound Edaravone Injection in
      Chinese Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Factorial Assignment</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC) of edaravone and 2-aminoethanesulfonic Acid in single dose groups of compound edaravone injection</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve (AUC) of edaravone and 2-aminoethanesulfonic Acid in multiple doses group after multiple intravenous infusion of compound edaravone injection</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of edaravone and 2-aminoethanesulfonic Acid in single dose groups of compound edaravone injection</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of edaravone and 2-aminoethanesulfonic Acid in multiple doses group after multiple intravenous infusion of compound edaravone injection</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of compound edaravone injection</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Compound Edaravone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mL per vial (containing edaravone 10 mg and 2-aminoethanesulfonic acid 200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 mL per vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1: Compound Edaravone/Placebo Injection</intervention_name>
    <description>Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min</description>
    <arm_group_label>Compound Edaravone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2: Compound Edaravone/Placebo Injection</intervention_name>
    <description>Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min</description>
    <arm_group_label>Compound Edaravone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 3: Compound Edaravone/Placebo Injection</intervention_name>
    <description>Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min</description>
    <arm_group_label>Compound Edaravone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 4: Compound Edaravone/Placebo Injection</intervention_name>
    <description>Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min</description>
    <arm_group_label>Compound Edaravone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 5: Compound Edaravone/Placebo Injection</intervention_name>
    <description>Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7</description>
    <arm_group_label>Compound Edaravone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-65 years old (including upper and lower limits);

          2. Weight ≥50 kg, body mass index (BMI) between 18-28 kg / m2 (including upper and lower
             limits);

          3. Understand and sign the informed consent voluntarily, and volunteer to participate in
             this research.

        Exclusion Criteria:

          1. A history of diseases of the heart, liver, lung, kidney, digestive tract, blood, or
             neuropsychiatric system judged by the investigator as clinically significant;

          2. A comprehensive physical examination, neurological examination, laboratory
             examination, ECG examination, or cognitive assessment indicates that the subject has
             an abnormality that the researcher has determined to be clinically significant;

          3. Have taken any drug within two weeks before the study administration, and the
             researcher believes that this situation may affect the evaluation results of this
             study;

          4. There is a history of food or drug allergy or allergies that the researcher judges to
             be clinically significant;

          5. Those with positive results of serological examination (HBsAg, anti-HCV, anti-HIV,
             TP-Ab);

          6. A history of alcohol or drug abuse that the investigator believes may affect the
             evaluation results of this study within one year before the study administration;

          7. Cannot quit smoking or drinking during the study period or the carbon monoxide breath
             test&gt; 7 ppm during the screening period CO breath test, so if the subject's CO breath
             is&gt; 7ppm, but the urine cotinine test is negative, it means that the CO breath test
             result may be false positive, the subject can be enrolled;

          8. As a subject who has participated in any drug clinical trial within 3 months before
             the first administration of the study;

          9. Those who donated blood or blood products ≥400 mL or 2 units within three months of
             the study;

         10. Do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or
             vigorous exercise, or other factors that affect drug absorption, distribution,
             metabolism, excretion, etc. during the 24 hours before and during the test;

         11. Pregnant or lactating women, or those who tested positive for serum HCG before the
             test administration, or those who were unable or unwilling to take researcher-approved
             contraception during the study according to the researcher's instructions;

         12. Subjects with poor compliance or unable to comply with the relevant provisions of the
             research protocol due to personal reasons, the investigator judges that the subjects
             are not suitable to participate in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Edaravone</keyword>
  <keyword>Compound edaravone injection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

